Hillary Norton, MD
Rheumatology · Santa Fe, NMNPI 1093911323
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,212,425 of the $1,884,601 with a category attached, or 64.3%. 34 manufacturers reported payments, led by AbbVie at 33.8% of the total. Reporting peaked in 2019 at $451,728 and has fallen 57.2% since, to $193,173 in 2025. Among rheumatology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,562 payments — averaging $735.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$637K
- UCB, Inc.$294K
- Lilly USA, LLC$249K
- Novartis$195K
- Amgen$140K
- Johnson & Johnson$95K
- plus $274K from 28 others
Across 135 payments — averaging $24,313 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.4M
- Novartis$456K
- Eli Lilly$167K
- Sanofi US Services Inc.$105K
- AbbVie$95K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- plus $17K from 4 others
What the payments were for
- Consulting fees$375,63920%
- Speaking & faculty fees$1,212,42564%
- Travel & lodging$252,98113%
- Food & beverage$43,1872%
- Education$3690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 729 | $637,025 |
| UCB, Inc. | 388 | $294,357 |
| Lilly USA, LLC | 407 | $249,195 |
| Novartis | 208 | $194,763 |
| Amgen(2 entities) | 265 | $139,880 |
| Johnson & Johnson | 116 | $95,360 |
| Janssen Scientific Affairs, LLC | 70 | $77,694 |
| AstraZeneca | 120 | $66,167 |
| Pfizer | 72 | $59,508 |
| Sanofi | 23 | $15,479 |
| Eli Lilly | 26 | $14,098 |
| Bristol Myers Squibb | 27 | $9,843 |
| E.r. Squibb & Sons, L.L.C. | 19 | $9,698 |
| Averitas Pharma Inc. | 4 | $5,378 |
| Regeneron | 12 | $5,229 |
| Regeneron Healthcare Solutions, Inc. | 10 | $3,819 |
| Sobi, Inc | 6 | $2,433 |
| UCB SA | 2 | $1,710 |
| UCB Biosciences Inc. | 1 | $1,575 |
| Sanofi-aventis U.S. LLC | 15 | $376 |
| GSK | 11 | $222 |
| Mallinckrodt Hospital Products Inc. | 6 | $163 |
| PBG Puerto Rico LLC | 1 | $103 |
| Genentech USA, Inc. | 5 | $99 |
| Radius Health, Inc. | 5 | $91 |
| Mallinckrodt Enterprises LLC | 3 | $66 |
| Boehringer Ingelheim | 2 | $61 |
| Arcutis Biotherapeutics, Inc. | 1 | $52 |
| Tersera Therapeutics LLC | 2 | $50 |
| Organon | 2 | $38 |
| Gilead | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,884,601 in reported general payments places this provider in the 95th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 29 | $225,786 |
| EnbrelEtanercept | 23 | $169,181 |
| Enbrel SureclickEtanercept | 14 | $164,500 |
| RinvoqUpadacitinib | 19 | $152,964 |
| Enbrel MiniEtanercept | 17 | $148,096 |
| Taltz AutoinjectorIxekizumab | 12 | $83,413 |
| Xeljanz XrTofacitinib Citrate | 14 | $80,273 |
| KevzaraSarilumab | 18 | $76,907 |
| OtezlaApremilast | 15 | $71,285 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $60,064 |
| Actemra ActpenTocilizumab | 13 | $59,009 |
| Hydroxychloroquine Sulfate | 281 | $8,399 |
| MethotrexateMethotrexate Sodium | 221 | $5,562 |
| Prednisone | 513 | $4,074 |
| Leflunomide | 55 | $3,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $139,880 | $240,46638 claims |
| AbbVieRinvoq | $637,025 | $152,96419 claims |
| SanofiKevzara | $15,479 | $76,90718 claims |
| UCB, Inc.Cimzia (2 Pack) | $294,357 | $60,06411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 rheumatology providers in New Mexico.
Other rheumatology in Santa Fe
- Susan BarrettSanta Fe$7K
- Rebecca FitzpatrickSanta Fe$1K
- Silver SisnerosSanta Fe$551
- Lyle AmerSanta Fe$55
- Ahmad RamahiRoswell$35K
- Adrian Michaella Mesilla$16K
- Wilmer SibbittAlbuquerque$9K
- Arthur SnyderLas Cruces$9K
- Leroy PachecoAlbuquerque$8K
- Albert RizzoliAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.